Freedom of Information request about the assessment report for the indication of “symptomatic treatment of severe sialorrhea” for Glycopyrronium Bromide 1mg Tablets (FOI-21-280))
Published 28 May 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-19-april/freedom-of-information-request-about-the-assessment-report-for-the-indication-of-symptomatic-treatment-of-severe-sialorrhea-for-glycopyrronium-bromi
In response to your request for a copy of the assessment report for the indication of “symptomatic treatment of severe sialorrhea” for Glycopyrronium Bromide 1mg Tablets (PL 44710/0017), I can confirm that the MHRA does hold this.
We intend to update the Public Assessment Report (PAR) for this product with the assessment of this indication in the near future.
As we plan to publish the assessment report in the near future, your request is refused under Section 22 of the Freedom of Information Act (information intended for future publication) and the information you have asked for is, therefore, exempt from disclosure.
Section 22 is a qualified exemption, which means a consideration of the public interest is necessary. We have considered the public interest and cannot see any public interest argument that necessitates MHRA to release the assessment report before this is published in the PAR. Examples of public interest arguments would be a major public health risk, or a major procedural failure or irregularity.
If you have a query about the information provided, please reply to this email.
If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk
Due to the ongoing Covid-19 situation, we are not able to accept delivery of any documents or correspondence by post or courier to any of our offices
Please remember to quote the reference number above in any future communications.
If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:
Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Yours sincerely
MHRA Customer Service Centre
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU Telephone 0203 080 6000